Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis

Journal of the American Academy of Dermatology

Volumn 46, Issue 2, 2002, Pages 228-241

  Nghiem, Paul ^a   Pearson, Greg ^b   Langley, Richard G ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b University of Missouri   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PIMECROLIMUS; TACROLIMUS;

ACNE; ARTICLE; ATOPIC DERMATITIS; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; FLU LIKE SYNDROME; FOLLICULITIS; HEADACHE; HUMAN; HYPERESTHESIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; PROKARYOTE; PRURITUS; SKIN ABSORPTION; SKIN CYST; SKIN INFECTION; SKIN IRRITATION; SKIN PENETRATION; SKIN TINGLING;

EID: 0036165478     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.120942     Document Type: Article

References (60)

1. Molecular cloning and overexpression of the human FK506-binding protein FKBP
2. Cyclophilin: A specific cytosolic binding protein for cyclosporin A
3. The mechanism of action of cyclosporin A and FK506
4. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin
5. Probing immunosuppressant action with a nonnatural immunophilin ligand
6. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
7. Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from alpha-factor arrest in yeast
8. Protein phosphatase type 2B (calcineurin)-mediated, FK506sensitive regulation of intracellular ions in yeast is an important determinant for adaptation to high salt stress conditions
9. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans
10. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons
11. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
12. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A
13. Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity
14. NF-ATp: A transcription factor required for the co-ordinate induction of several cytokine genes
15. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin
16. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription
17. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506)
18. Absorption of topical tacrolimus (FK506) in vitro through human skin: Comparison with cyclosporin A
19. Tacrolimus ointment for atopic dermatitis
20. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment
21. A short-term trial of tacrolimus ointment for atopic dermatitis
22. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
23. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
24. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis
25. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study
26. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
27. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
28. Safety and efficacy of ASM 981 (pimecrolimus) cream 1% in the treatment of atopic dermatitis in children and adolescents
29. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
30. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis
31. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis
32. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome
33. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system (comparison with steroids)
34. Tacrolimus (FK 506): A new therapeutic agent for severe recalcitrant psoriasis
35. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study
36. Topical tacrolimus is not effective in chronic plaque psoriasis: A pilot study
37. Topical tacrolimus is effective for facial lesions of psoriasis
38. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
39. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum
40. Resolution of pyoderma gangrenosum using tacrolimus (FK-506)
41. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum
42. Parastomal pyoderma gangrenosum: Clinical features and management
43. Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum
44. Pyoderma gangrenosum: Classification and management
45. FK506 in the treatment of inflammatory skin disease: Promises and perspectives
46. Erosive mucosal lichen planus: Response to topical treatment with tacrolimus
47. The "drug vs graft-vs-host disease" conundrum gets tougher, but there is an answer: The challenge to dermatologists
48. Uses and growth of hematopoietic cell transplantation
49. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: A case series of 18 patients
50. Topical tacrolimus: Treatment failure in a patient with alopecia areata
51. Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants
52. Hair growth modulation by topical immunophilin ligands: Induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia
53. Inhibition of contact allergy reactions by topical FK506
54. Topical FKS06 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses
55. Tacrolimus ointment for the treatment of steroidinduced rosacea: A preliminary report
56. A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus
57. Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis
58. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex
59. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety